ABCL vs AKTS: fair value comparison
AbCellera Biologics Inc. and Aktis Oncology, Inc. · Updated 2026-10-19
ABCL has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. AKTS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, ABCL currently ranks higher by quality score.
| ABCL | AKTS | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $11.80 | $15.06 |
| 12-month range | $2.78–$14.82 | $15.06–$30.89 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #172 of 301 Healthcare | #174 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Contracting | Expanding |
| Revenue growth | Declining | Declining |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Mixed | — |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: ABCL fair value analysis · AKTS fair value analysis